Karlan BY - Search Results

1

Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers.

Mejia-Gomez J, Gronwald J, Senter L, Karlan BY, Tung N, Wolfman W, Demsky R, Sun P, Narod SA, Kotsopoulos J; and the Hereditary Breast Cancer Clinical Study Group. Mejia-Gomez J, et al. Among authors: karlan by. Menopause. 2020 Dec;27(12):1396-1402. doi: 10.1097/GME.0000000000001629. Menopause. 2020. PMID: 32796289

2

No association of the I1307K APC allele with ovarian cancer risk in Ashkenazi Jews.

Abrahamson J, Moslehi R, Vesprini D, Karlan B, Fishman D, Smotkin D, Ben David Y, Biran H, Fields A, Brunet JS, Narod SA. Abrahamson J, et al. Cancer Res. 1998 Jul 15;58(14):2919-22. Cancer Res. 1998. PMID: 9679945

3

Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening.

Karlan BY, Baldwin RL, Lopez-Luevanos E, Raffel LJ, Barbuto D, Narod S, Platt LD. Karlan BY, et al. Am J Obstet Gynecol. 1999 Apr;180(4):917-28. doi: 10.1016/s0002-9378(99)70663-0. Am J Obstet Gynecol. 1999. PMID: 10203660

4

BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.

Moslehi R, Chu W, Karlan B, Fishman D, Risch H, Fields A, Smotkin D, Ben-David Y, Rosenblatt J, Russo D, Schwartz P, Tung N, Warner E, Rosen B, Friedman J, Brunet JS, Narod SA. Moslehi R, et al. Am J Hum Genet. 2000 Apr;66(4):1259-72. doi: 10.1086/302853. Epub 2000 Mar 16. Am J Hum Genet. 2000. PMID: 10739756 Free PMC article.

5

BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.

Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S, Karlan BY. Baldwin RL, et al. Among authors: karlan by. Cancer Res. 2000 Oct 1;60(19):5329-33. Cancer Res. 2000. PMID: 11034065

6

Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.

Narod SA, Sun P, Ghadirian P, Lynch H, Isaacs C, Garber J, Weber B, Karlan B, Fishman D, Rosen B, Tung N, Neuhausen SL. Narod SA, et al. Lancet. 2001 May 12;357(9267):1467-70. doi: 10.1016/s0140-6736(00)04642-0. Lancet. 2001. PMID: 11377596

7

Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives.

Runnebaum IB, Wang-Gohrke S, Vesprini D, Kreienberg R, Lynch H, Moslehi R, Ghadirian P, Weber B, Godwin AK, Risch H, Garber J, Lerman C, Olopade OI, Foulkes WD, Karlan B, Warner E, Rosen B, Rebbeck T, Tonin P, Dubé MP, Kieback DG, Narod SA. Runnebaum IB, et al. Pharmacogenetics. 2001 Oct;11(7):635-8. doi: 10.1097/00008571-200110000-00010. Pharmacogenetics. 2001. PMID: 11668223

8

Cancer incidence in a population of Jewish women at risk of ovarian cancer.

Liede A, Karlan BY, Baldwin RL, Platt LD, Kuperstein G, Narod SA. Liede A, et al. Among authors: karlan by. J Clin Oncol. 2002 Mar 15;20(6):1570-7. doi: 10.1200/JCO.2002.20.6.1570. J Clin Oncol. 2002. PMID: 11896106

9

Improved survival in women with BRCA-associated ovarian carcinoma.

Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Cass I, et al. Among authors: karlan by. Cancer. 2003 May 1;97(9):2187-95. doi: 10.1002/cncr.11310. Cancer. 2003. PMID: 12712470 Free article.

10

Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States).

Modugno F, Moslehi R, Ness RB, Nelson DB, Belle S, Kant JA, Wheeler JE, Wonderlick A, Fishman D, Karlan B, Risch H, Cramer DW, Dube MP, Narod SA. Modugno F, et al. Cancer Causes Control. 2003 Jun;14(5):439-46. doi: 10.1023/a:1024932427503. Cancer Causes Control. 2003. PMID: 12946038

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

511 results

Search Page